(Q37867350)

24 August 2017

1 reference

title

The role of the renin-angiotensin system in liver fibrosis (English)

1 reference

24 August 2017

M Kamruzzman Munshi

1

1 reference

24 August 2017

Mohammad N Uddin

series ordinal

2

1 reference

24 August 2017

Shannon S Glaser

series ordinal

3

1 reference

24 August 2017

publication date

20 April 2011

1 reference

Experimental Biology and Medicine

24 August 2017

published in

1 reference

24 August 2017

volume

236

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

557-566

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

24 August 2017

1 reference

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Mechanisms of hepatic fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

The global impact of hepatic fibrosis and end-stage liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Chronic liver injury, TGF-beta, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Transforming growth factor beta and the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Liver fibrogenesis: a new role for the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Renin-angiotensin system in the pathogenesis of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Cellular and molecular mechanisms of liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Cholangiocyte proliferation and liver fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Wound healing and local neuroendocrine regulation in the injured liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

The cholangiopathies: disorders of biliary epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

The renin–angiotensin system in a rat model of hepatic fibrosis: Evidence for a protective role of Angiotensin-(1–7)

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Regulation of renin: new evidence from cultured cells and genetically modified mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Local generation of angiotensin II as a mechanism of regulation of peripheral vascular tone in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Mechanisms of angiotensin II formation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Physiology of local renin-angiotensin systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Update on tissue renin-angiotensin systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

New pathways of the renin-angiotensin system: the role of ACE2 in cardiovascular pathophysiology and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Expression and localization of AT1 receptors in hepatic Kupffer cells: its potential role in regulating a fibrogenic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Localization of Angiotensinogen in Rat Liver by Immunocytochemistry*

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Hepatorenal disorders: role of the renin-angiotensin-aldosterone system

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Relationship between angiotensin-(1-7) and angiotensin II correlates with hemodynamic changes in human liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Angiotensin II and renal fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Effects of AT1- and beta-adrenergic receptor antagonists on TGF-beta1-induced fibrosis in transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Liver disease and the renin-angiotensin system: recent discoveries and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Benefits of the RAS blockade: clinical evidence before the ONTARGET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Renin, aldosterone and renal haemodynamics in cirrhosis with ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

Angiotensin II induces tumor progression and fibrosis in intrahepatic cholangiocarcinoma through an interaction with hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2011.010375

21 January 2018

Identifiers

DOI

10.1258/EBM.2011.010375

1 reference

24 August 2017

1 reference